Genetic fingerprints help predict sarcoma outcome:
This article was originally published in Clinica
US researchers have developed a genetic fingerprint of each type of adult soft tissue sarcoma, which they say will improve their diagnosis and enhance the prediction of patient outcome. The genetic fingerprints, which were identified using oligonucleotide array analysis, will be useful in cases where pathologists disagree about a diagnosis or when the appearance of tumour cells does not conclusively link them to a particular subtype, say researchers led by Dr Robert Maki, of the Memorial Sloan-Kettering Cancer Center in New York.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.